University of Kentucky Markey Cancer Center Neuro-Oncology Multi-Disciplinary Tumor Board Protocol for the Treatment of Advanced Brain Metastases
- Sponsor
- John L. Villano, MD, PhD
- Study ID
- NCT07786311
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Brain Metastases
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- Neuro-Oncology Multi-Disciplinary Tumor Board Review — OTHERParticipants with brain metastases undergo review by the Markey Cancer Center Neuro-Oncology Multi-Disciplinary Tumor Board. Treatment recommendations may include surgery, radiation therapy, systemic therapy, observation, or referral to additional clinical trials. Outcomes including adherence to recommendations and overall survival will be assessed.
Study Details
This study evaluates whether review by the University of Kentucky Markey Cancer Center Neuro-Oncology Multidisciplinary Tumor Board improves clinical outcomes for adults with advanced brain metastases. Participants receive standard-of-care treatment as determined by their treating physicians. The study assesses whether multidisciplinary tumor board review and implementation of its treatment recommendations are associated with improved overall survival, progression-free survival, treatment selection and other clinical outcomes compared with patients who do not adhere to the tumor board recommendations.
Key Dates
- First listed
- Aug 25, 2026
- Start date
- Sep 30, 2026
- Status verified
- Aug 2026
- Primary completion
- Sep 30, 2029
- Completion
- Mar 31, 2030
Study Design
- Enrollment
- 125 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Neuro-Oncology Multi-Disciplinary Tumor Board ReviewParticipants with brain metastases undergo review by the Markey Cancer Center Neuro-Oncology Multi-Disciplinary Tumor Board. Treatment recommendations may include surgery, radiation therapy, systemic therapy, observation, or referral to additional clinical trials. Outcomes including adherence to recommendations and overall survival will be assessed.
Primary Outcome Measure
Adherence to Neuro-Oncology Multi-Disciplinary Tumor Board Treatment Recommendations [ Time Frame: Up to 3 years ]
Related Studies
- Stereotactic Radiosurgery Dose Escalation for Brain MetastasesPHASE1 · Recruiting · University of Utah · Salt Lake City, Utah
- Frameless Stereotactic Radiosurgery for Intact Brain MetastasesPHASE2 · Recruiting · University of Chicago · Chicago, Illinois
- Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer PatientsPHASE1/PHASE2 · Recruiting · Weill Medical College of Cornell University · New York, New York
- Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain MetastasesPHASE3 · Recruiting · Canadian Cancer Trials Group · Tucson, Arizona